Despite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
Spanish Ferrer SA pays €122.5m for ALS candidate
Latest NewsSpanish Ferrer Internacional, SA has aquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialise the oral Phase I experimental ALS treatment.
SMEs suffer from CTIS
OpinionBorn with the aim of harmonising the application, evaluation, and supervision process of clinical trials conducted in EU countries, there is much room for improvement for the Clinical Trial Information System CTIS, particularly with regard to SMEs and translational researchers.
Novo Nordisk to acquire Cardior Pharmaceuticals
Latest NewsNovo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.
NDM Pharma provides POC for NMD670
Latest NewsResearchers at NDM Pharma A/S and Aarhus University have demonstrated that their oral CIC-1 blocker NMD670 restores crosstalk between neurons and muscles in Myasthenia gravis.
Roche opens €90m gene therapy development centre
Latest NewsBasel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.
AstraZeneca to take over Fusion Therapeutics Inc
Latest NewsBritish pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.
Senisca Ltd raises £3.7m seed money
Latest NewsExeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.
Are there bright times for biotech IPOs ahead?
OpinionDespite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
Meeting rising demand
Sponsored PublicationsRadiopharmaceutical Therapy (RPT) is offering several advantages over existing therapeutic strategies. The highly sought-after therapeutics require a sophisticated supply chain, as radioisotopes have short half-lives and must be delivered to patients with extreme speed and efficiency. ITM rises to this challenge as one of the largest global providers and developers of medical radioisotopes for this novel therapy.
A novel BPM system
BackgroundThe biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These growing structures often expose vulnerabilities and challenges for the business. Therefore, companies need to increase the stability and efficiency of their processes.